Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.33 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9106492 | 0.95 | MAPT (0.38) | MAPTPOLBRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL9102493 | 0.91 | MAPT (0.44) | MAPTPOLBRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL9106284 | 0.91 | MAPT (0.37) | MAPTPOLBRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL9105487 | 0.87 | S1PR3 (0.39) | MAPTPOLBRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL9102537 | 0.87 | MAPT (0.37) | MAPTPOLBRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL9108212 | 0.86 | MAPT (0.38) | MAPTPOLBRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL9108232 | 0.86 | MAPT (0.38) | MAPTPOLBRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL9104139 | 0.85 | HTT (0.37) | MAPTRAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL9100806 | 0.83 | NPC1 (0.38) | MAPTPOLBRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL9104063 | 0.81 | MAPT (0.38) | MAPTPOLBRAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2646026-B1 | NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2014-10-15 | — | — | EP | claimed |
| US-20140057952-A1 | NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-02-27 | — | — | US | claimed |
| US-8618139-B2 | Oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2013-12-31 | — | — | US | claimed |
| EP-2646026-A1 | NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | Allergan, Inc. (US) | 2013-10-09 | — | — | EP | claimed |
| WO-2012074718-A1 | NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | WO | claimed |
| US-20120142739-A1 | NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | claimed |
| EP-2646026-B1 | NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2646026-B1 | NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20140057952-A1 | NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057952-A1 | NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057952-A1 | NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8618139-B2 | Oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators | ALLERGAN, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| EP-2646026-A1 | NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | Allergan, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012074718-A1 | NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142739-A1 | NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142739-A1 | NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142739-A1 | NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057952-A1 | NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR3, S1PR1, S1PR2 | MAPT 3079/4885POLB 4375/4885RAB9A 3307/4885 |
| US-20120142739-A1 | NOVEL OXADIAZOLE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS | S1PR3, S1PR1, S1PR2 | MAPT 3079/4885POLB 4375/4885RAB9A 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.